Precision Immune Rejuvenation: Rebuilding the T-Cell Factory
At Adaptive Biologics, our long-term vision builds directly on the foundation we are establishing today. Having validated our proprietary plant-based biopharming platform with Thymosin α1 (Tα1) — our lead program for scalable, ultra-pure immune-modulating peptides — we are now advancing toward a transformative application: the First-Hit Strategy. We will harness the same superior platform that delivers unmatched safety, purity, cost-efficiency, and protein quality to produce an entire suite of thymopoietic peptides. These will power the world’s first precision protocol for surgical reconstruction of the human thymus — the body’s T-cell factory — before deploying modern immunotherapy.
Why This Matters: Overcoming Immunological Bankruptcy. By middle age, thymic involution replaces most functional thymic tissue with fat. The result is a collapsed T-cell receptor repertoire, reduced naïve T-cell output, and exhausted immune responses that severely limit the effectiveness of today’s checkpoint inhibitors in 60–70% of solid tumor cases. Our solution is simple and powerful: Rebuild the factory first.
The First-Hit Protocol: A New Standard in Immune Engineering. Phase 1: Neoadjuvant Systemic Priming. Using our plant-derived IL-7 and Zinc-Thymulin to safely increase thymic density and cellularity, creating a clear, MRI-visible target — without stimulating tumor growth. Phase 2: Precision Access. Implantation of our proprietary Trans-Sternal Access Conduit (TSAC) — a titanium-threaded, bone-anchored, self-sealing delivery system that provides stable, permanent (or indication-specific temporary) localized access to the mediastinum with 100% bioavailability and minimal systemic exposure. Phase 3: Localized Organ Regeneration. Direct delivery via the TSAC of a regenerative hydrogel containing FGF-7 (KGF), IGF-1, and our high-purity Thymosin α1. These potent factors are caged within the thymus to trigger true organ-level hyperplasia while shielding the rest of the body — and the tumor — from unwanted growth signals. Phase 4: Immunological Unleash. A rejuvenated thymus releases a fresh, diverse pool of properly educated naïve T-cells. Standard-of-care checkpoint immunotherapy is then administered, dramatically improving tumor clearance and reducing immune-related adverse events.
Powered by Our Platform Advantage
Every peptide in the First-Hit protocol will be manufactured using the same proprietary plant-based system that already outperforms traditional methods in purity (zero mammalian contaminants, viruses, prions, or endotoxins), scalability, cost, and human-compatible protein folding. This ensures micro-dosing capability, exceptional safety, and the economic viability needed for both oncology and longevity applications.
Built-In Safety & Patient-Centric Design. Localized Tα1 delivery supports rigorous negative selection to minimize autoimmunity risk. Pulsed, thymus-confined growth factors eliminate systemic mitogenic concerns. Advanced Bio-Lock protocols and osseointegrated TSAC design reduce infection risk. Biomarker-driven patient selection (thymic imaging scores, TREC levels, TCR repertoire analysis) ensures optimal responders. Adaptive Biologics is not simply manufacturing better peptides — we are engineering a superior immune system from the ground up.
Join the journey
We invite visionary researchers, clinicians, thoracic surgeons, immuno-oncologists, and forward-thinking investors to collaborate with us as we move from platform validation to clinical impact.
Interested in our progress or partnership opportunities? Contact us at Nichlosanglin@Adaptive-biologics.com. The immune factory is ready to be rebuilt. The future of precision immune engineering starts here.